olaparib
Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay
Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel.
Clovis Oncology's Q2 Rubraca Sales Dip 8 Percent
The company attributed lower revenues to the negative impact from the COVID-19 pandemic but highlighted its ongoing R&D efforts to expand the drug's indication.
Merck Q2 Revenues Grow 22 Percent
The company's pharmaceutical revenues were led by robust sales of Keytruda, which racked up $4.18 billion during the quarter.
AstraZeneca Q2 Revenues Increase 31 Percent
The company reported revenues of $8.22 billion, largely driven by sales of its COVID-19 vaccine, but also due to strong performance of its oncology segment.
Chinese Regulators Approve Lynparza for BRCA1/2-Mutated mCRPC
China's NMPA granted conditional approval to AstraZeneca and Merck's PARP inhibitor in this setting based on the results of the PROfound trial.